« Previous article
New Animal-Free Mono...

12th October 2020  Content supplied by: Lonza Pharma&Biotech - Bioscience Solutions

"Error-proofing" and "Future-proofing": Updating the BET


The use of robotics and automation reduces error levels common to many manual processes, thus saving time and resources spent on such tasks. Studies comparing manual and automated pipetting and mixing in the BET test show improved precision and accuracy with the automated method. With such automation, laboratory analysts are freed to perform other tasks while a robot performs the manual tasks, resulting in more efficient use of that analyst’s time. Automation of BET methods minimizes the level of interaction with lab analysts, resulting in a reduced level of repetitive motion injuries in line with promulgated regulations for workers protection.

In addition to the use of robotics for error-proofing the assay, there is also a need to future-proof the supply chain of reagents. Using a recombinant reagent allows removal of the live animal source thus complying with the “3 R” principles (replacement, reduction, refinement of animal use), multiple facility production of the reagent (not reliant on a single production facility), and results in a more stable supply chain of a reagent with less lot-to-lot variability. Recombinant Factor C (rFC) based endotoxin detection assays demonstrate equivalent performance when compared to classical LAL-based assays.


    

Tags:

Date Published: 12th October 2020

Source article link: View


View full company details




Lonza Pharma&Biotech - Bioscience Solutions

Address:

8830 Biggs Ford Road, Walkersville

United States

Tel: +[1] 800-521-0390

Email Supplier

View full company details


Related news from Lonza Pharma&Biotech - Bioscience Solutions